Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Epigenomics
|
November 8, 2012
Chromatin regulators with tumor suppressor properties and their alterations in human cancers
Xing-Sheng Shu, Lili Li, Qian Tao
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
April 9, 2023
Targeting cancer metabolic vulnerabilities for advanced therapeutic efficacy
Tobias Achu Muluh, Xing-Sheng Shu, Ying Ying
Neuropharmacology
|
February 14, 2021
Targeted pharmacotherapy against neurodegeneration and neuroinflammation in early diabetic retinopathy
Kostadin Dimov Rolev, Xing-Sheng Shu, Ying Ying
Chinese Journal of Cancer
|
March 29, 2011
Epigenetic disruption of cell signaling in nasopharyngeal carcinoma
Li-Li Li, Xing-Sheng Shu, Zhao-Hui Wang, et al.
Oncotarget
|
April 14, 2017
OSR1 is a novel epigenetic silenced tumor suppressor regulating invasion and proliferation in renal cell carcinoma
Yixiang Zhang, Yeqing Yuan, Pei Liang, et al.
Aging
|
June 24, 2020
Loss of β-catenin via activated GSK3β causes diabetic retinal neurodegeneration by instigating a vicious cycle of oxidative stress-driven mitochondrial impairment
Xing-Sheng Shu, Huazhang Zhu, Xiaoyan Huang, et al.
Cell Death & Disease
|
January 7, 2023
A distal super-enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease and colorectal cancer
Yongheng Chen, Ying Ying, Maolin Wang, et al.
The Journal of Pathology
|
September 24, 2017
The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid-inducible gene-I-like receptor signalling and is a potential prognostic biomarker for colon cancer
Xing-Sheng Shu, Yingying Zhao, Yanmei Sun, et al.
Antioxidants & Redox Signaling
|
July 3, 2024
Targeting Ferroptosis as an Advance Strategy in Cancer Therapy
Tobias Achu Muluh, Qianqian Fu, Xiaojiao Ai, et al.
Frontiers in Oncology
|
December 3, 2021
A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer
Maolin Wang, Xing-Sheng Shu, Meiqi Li, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Epigenomics
|
November 8, 2012
Chromatin regulators with tumor suppressor properties and their alterations in human cancers
Xing-Sheng Shu, Lili Li, Qian Tao
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
April 9, 2023
Targeting cancer metabolic vulnerabilities for advanced therapeutic efficacy
Tobias Achu Muluh, Xing-Sheng Shu, Ying Ying
Neuropharmacology
|
February 14, 2021
Targeted pharmacotherapy against neurodegeneration and neuroinflammation in early diabetic retinopathy
Kostadin Dimov Rolev, Xing-Sheng Shu, Ying Ying
Chinese Journal of Cancer
|
March 29, 2011
Epigenetic disruption of cell signaling in nasopharyngeal carcinoma
Li-Li Li, Xing-Sheng Shu, Zhao-Hui Wang, et al.
Oncotarget
|
April 14, 2017
OSR1 is a novel epigenetic silenced tumor suppressor regulating invasion and proliferation in renal cell carcinoma
Yixiang Zhang, Yeqing Yuan, Pei Liang, et al.
Aging
|
June 24, 2020
Loss of β-catenin via activated GSK3β causes diabetic retinal neurodegeneration by instigating a vicious cycle of oxidative stress-driven mitochondrial impairment
Xing-Sheng Shu, Huazhang Zhu, Xiaoyan Huang, et al.
Cell Death & Disease
|
January 7, 2023
A distal super-enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease and colorectal cancer
Yongheng Chen, Ying Ying, Maolin Wang, et al.
The Journal of Pathology
|
September 24, 2017
The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid-inducible gene-I-like receptor signalling and is a potential prognostic biomarker for colon cancer
Xing-Sheng Shu, Yingying Zhao, Yanmei Sun, et al.
Antioxidants & Redox Signaling
|
July 3, 2024
Targeting Ferroptosis as an Advance Strategy in Cancer Therapy
Tobias Achu Muluh, Qianqian Fu, Xiaojiao Ai, et al.
Frontiers in Oncology
|
December 3, 2021
A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer
Maolin Wang, Xing-Sheng Shu, Meiqi Li, et al.
Page
of 3